FGFR2 gene fusion is observed in approximately 14% of intrahepatic cholangiocarcinoma, which accounts for 15%-30% of all biliary tract cancers, according to Eisai, but drug options are limited.

The Bismuth–Corlette classification system provides an anatomic description ... They often manifest as a concentric thickening of the bile duct, coupled with infiltration of the periductal ...

Eisai has launched its new therapy for biliary tract cancer (BTC ... patients with this type of cancer – which is also known as cholangiocarcinoma. It was approved by the MHLW on the strength ...

Selective deep cannulation of the common bile duct remains the key rate-limiting step in successful endoscopic retrograde cholangiopancreatography (ERCP), especially in benign biliary disease.

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The ...

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...